A Phase 2/3 interventional study of vorinostat and Comparator: paclitaxel in Stage IIIB or IV Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2007, is the only one in phase 2/3, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 9 · Phase 3 1
First in 2001; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 21 across the 19 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 38th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2007, is one of 2 in phase 2/3, and was the 12th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vorinostat; IV paclitaxel; IV carboplatin
Drug: vorinostat · Drug: Comparator: paclitaxel · Drug: Comparator: carboplatin
Placebo; IV paclitaxel; IV carboplatin
Drug: Comparator: paclitaxel · Drug: Comparator: carboplatin · Drug: Comparator: placebo
vorinostat 400 mg capsules once daily. Up to 6 months of treatment
Also known as: Zolinza
intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
Also known as: Taxol
intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
Also known as: Paraplatin
vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
Overall Survival
Defined as the time from date of randomization to death due to any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up.
Time frame: Start of treatment to death
Progression Free Survival
Defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in sum of the longest diameter of all target lesions, the appearance of a new lesion, or an increase in non-target lesions.
Time frame: Start of treatment to disease progression or death
Number of Participants Who Had a Disease Response to Treatment
Response to treatment is defined as a complete response (CR) or partial response (PR) to treatment. Confirmation of response required a second assessment performed at least 4 weeks after the initial assessment. (PR is defined as at least a 30% reduction in sum of the longest diameter of all target lesions and no increase in non-target lesions).
Time frame: Every 42 days from start of treatment until disease response
This study was conducted at 99 investigative sites worldwide. The first patient's first visit was 16 May 07 and the last patient's last visit was 12 Dec 2008.
| Milestone | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin |
|---|---|---|
| Started | 126 | 127 |
| Completed | 43 | 63 |
| Not completed | 83 | 64 |
| Withdrew: Did not receive study medication | 1 | 4 |
| Withdrew: Adverse event | 30 | 17 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Lack of efficacy | 28 | 29 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 10 | 5 |
| Withdrew: Trial terminated | 3 | 6 |
| Withdrew: Withdrawal by subject | 5 | 0 |
Defined as the time from date of randomization to death due to any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up.
| Months | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin |
|---|---|---|
| Overall Survival | 11.0 (0.2 to 17.3) | 14.0 (0.03 to 18.7) |
Defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in sum of the longest diameter of all target lesions, the appearance of a new lesion, or an increase in non-target lesions.
| Months | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin |
|---|---|---|
| Progression Free Survival | 4.3 (0.03 to 13.4) | 5.5 (0.03 to 13.8) |
Response to treatment is defined as a complete response (CR) or partial response (PR) to treatment. Confirmation of response required a second assessment performed at least 4 weeks after the initial assessment. (PR is defined as at least a 30% reduction in sum of the longest diameter of all target lesions and no increase in non-target lesions).
| Participants | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin |
|---|---|---|
| Responder | 28 | 36 |
| Non-Responder | 97 | 87 |
Collected over Adverse Events were collected from the time the patient signed the informed consent form until 30 days after the last dose of study medications. Serious Adverse Events were followed until resolution.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat + Paclitaxel + Carboplatin | — | 63/124 (50.8%) | 114/124 (91.9%) |
| Placebo + Paclitaxel + Carboplatin | — | 45/124 (36.3%) | 117/124 (94.4%) |
| Event | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin |
|---|---|---|
| PneumoniaInfections and infestations | 11/124 | 9/124 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/124 | 11/124 |
| Febrile neutropeniaBlood and lymphatic system disorders | 10/124 | 5/124 |
| NeutropeniaBlood and lymphatic system disorders | 9/124 | 2/124 |
| AstheniaGeneral disorders | 6/124 | 1/124 |
| PyrexiaGeneral disorders | 5/124 | 2/124 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/124 | 2/124 |
| DiarrhoeaGastrointestinal disorders | 4/124 | 1/124 |
| DehydrationMetabolism and nutrition disorders | 4/124 | 0/124 |
| AnaemiaBlood and lymphatic system disorders | 2/124 | 3/124 |
| Event | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin |
|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 51/124 | 61/124 |
| NeutropeniaBlood and lymphatic system disorders | 53/124 | 55/124 |
| AnaemiaBlood and lymphatic system disorders | 51/124 | 42/124 |
| AlopeciaSkin and subcutaneous tissue disorders | 41/124 | 47/124 |
| NauseaGastrointestinal disorders | 46/124 | 39/124 |
| ThrombocytopeniaBlood and lymphatic system disorders | 45/124 | 23/124 |
| DiarrhoeaGastrointestinal disorders | 43/124 | 36/124 |
| MyalgiaMusculoskeletal and connective tissue disorders | 21/124 | 36/124 |
| ConstipationGastrointestinal disorders | 34/124 | 26/124 |
| VomitingGastrointestinal disorders | 34/124 | 24/124 |
| Age, Customized(participants) | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Less Than 65 years | 70 | 89 | 159 |
| 65 years or Older | 56 | 38 | 94 |
| Sex: Female, Male(Participants) | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Female | 34 | 56 | 90 |
| Male | 92 | 71 | 163 |
| Race/Ethnicity, Customized(participants) | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| White | 79 | 79 | 158 |
| Black | 3 | 4 | 7 |
| Asian | 31 | 32 | 63 |
| American Indian or Alaskan Native mix | 13 | 12 | 25 |
| Cancer Stage(Participants) | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| IIIB | 14 | 15 | 29 |
| IV | 112 | 112 | 224 |
| Eligibility to receive treatment with Bevacizumab(Participants) | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Eligible | 70 | 63 | 133 |
| Ineligible | 55 | 60 | 115 |
| Unknown | 1 | 4 | 5 |
| Geographic region where the participant lived(Participants) | Vorinostat + Paclitaxel + Carboplatin | Placebo + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| North America | 25 | 27 | 52 |
| Europe (United Kingdom, Italy, Germany, and Spain) | 41 | 40 | 81 |
| Asia | 22 | 24 | 46 |
| Rest of the World | 38 | 36 | 74 |
No study locations are listed for this record.
The record gives a start of May 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat
Carcinoma, Non-Small-Cell Lung →